LRRK2 and Parkinson disease: Among the LRRK2 inhibitors in clinical development, DNL201 and DNL151 were well tolerated in a phase I study in healthy volunteers [146]. Further, DNL201 was evaluated in a phase Ib trial assessing drug safety and pharmacokinetics in 28 patients with early PD.